Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scinai Immunotherapeutics Ltd SCNI

Healthcare Biotechnology
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more

Recent & Breaking News (NDAQ:SCNI)

BiondVax Announces Public Offering of American Depositary Shares

PR Newswire September 13, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  September 13, 2017

BiondVax Provides Second Quarter 2017 Financial Results and Update

PR Newswire August 31, 2017

Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange

PR Newswire August 31, 2017

BiondVax Receives Additional Grant Funding

PR Newswire August 14, 2017

BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine

PR Newswire July 20, 2017

BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine

PR Newswire July 18, 2017

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  July 5, 2017

BiondVax's CEO Provides First Half 2017 General Corporate Update

PR Newswire June 28, 2017

European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative

PR Newswire June 19, 2017

BiondVax Announces First Quarter 2017 Financial Results and Update

PR Newswire May 30, 2017

18 Biggest Mid-Day Gainers For Monday

Benzinga.com  May 15, 2017

BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update

PR Newswire April 28, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  April 13, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 30, 2017

Mid-Morning Market Update: Markets Edge Higher; Lululemon Issues Weak Forecast

Benzinga.com  March 30, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 30, 2017

BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine

PR Newswire March 30, 2017

BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal

PR Newswire March 13, 2017

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  March 7, 2017